Treatment Intensification for Type 2 Diabetes with A1C 9.0%

Current Regimen Assessment

The patient's A1C of 9.0% indicates inadequate glycemic control despite dual therapy with metformin and a sulfonylurea (glipizide) 1, 2

Increase metformin to 1000 mg twice daily (2000 mg total daily) to maximize its effectiveness 1, 2, 4
Metformin should be maintained as the foundation of therapy due to its established efficacy, safety, and low cost 2, 4
Add a GLP-1 receptor agonist to the regimen as the preferred third agent 1, 2, 3
GLP-1 RAs provide significant A1C reduction (1-2% lowering) with additional benefits of weight reduction and low hypoglycemia risk 3
The combination of metformin, sulfonylurea, and GLP-1 RA addresses multiple pathophysiological defects in type 2 diabetes 3

For patients with A1C ≥9.0%, intensification of therapy is urgently needed 2, 5
The American Diabetes Association recommends combination injectable therapy when A1C remains above target despite oral agents 1, 2
GLP-1 RAs are preferred over insulin intensification for many patients due to lower risk of hypoglycemia compared to insulin intensification 3

Reassess A1C in 3 months after treatment adjustment 2, 3
Check vitamin B12 levels with long-term metformin use 3
If A1C target is not achieved after 3 months on optimized triple therapy, consider transitioning to insulin-based regimen 1, 2

Therapeutic inertia - delaying treatment intensification despite evidence of inadequate control 3
Continuing sulfonylurea when adding insulin (if insulin is eventually needed) - increases hypoglycemia risk 1
Not considering patient-specific factors like adherence, cost, and side effect profiles when selecting add-on therapy 2, 3